XORTX Pharma Corp.
Treating orphan and lifestyle diseases, uric acid metabolism causes health risks.
XORTX Pharma Corp is a drug development company focused on orphan diseases that have a uric acid (UA) imbalance. High UA is an independent risk factor for autosomal dominant polycystic kidney disease (ADPKD) progression. XORTX is developing oxypurinol to decrease UA and treat progressive kidney disease. Phase II trial successes show strong safe and effectiveness. Our business model is to complete phase II PoC in ADPKD then license.